What does S.A Therabel-Pharma N.V. do?

S.A Therabel-Pharma N.V. is a wholesaler in Vorst. Public Limited, started on 16 April 1980, 1 establishment.

What is the address of S.A Therabel-Pharma N.V.?

The registered office of S.A Therabel-Pharma N.V. is located at Humaniteitslaan 292, 1190 Vorst.

Is S.A Therabel-Pharma N.V. still active?

Yes. According to the CBE (16 September 2026) S.A Therabel-Pharma N.V. is active, legal situation “Normale toestand”, started on 16 April 1980.

Is S.A Therabel-Pharma N.V. registered on Peppol?

Yes, S.A Therabel-Pharma N.V. is registered on the Peppol network with ID 0208:0420515586.

What is the enterprise number of S.A Therabel-Pharma N.V.?

The enterprise number of S.A Therabel-Pharma N.V. is BE0420515586.

When was S.A Therabel-Pharma N.V. founded?

S.A Therabel-Pharma N.V. was founded on 16 April 1980.

Who are the directors of S.A Therabel-Pharma N.V.?

According to the 2025 annual accounts, the directors of S.A Therabel-Pharma N.V. are: Healthcare Expert Consulting SRL, Bawip Consultants SRL.

Is S.A Therabel-Pharma N.V. a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 April 1980; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did S.A Therabel-Pharma N.V. make in 2025?

S.A Therabel-Pharma N.V. recorded a loss after taxes of € 98,457 in financial year 2025.

What is the revenue of S.A Therabel-Pharma N.V.?

In its most recent annual accounts (2025), S.A Therabel-Pharma N.V. reported revenue of € 15,749,710.

How much does an employee at S.A Therabel-Pharma N.V. earn?

The average wage cost per full-time employee at S.A Therabel-Pharma N.V. was € 199,100 in 2025: staff costs of € 5.6 million for 28.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does S.A Therabel-Pharma N.V. have?

According to the 2025 annual accounts, S.A Therabel-Pharma N.V. has 28.3 full-time equivalents (FTE).

S.A Therabel-Pharma N.V. (Public Limited) - Vorst

Dossier S.A Therabel-Pharma N.V., printed on 16 September 2026 from databakkes.be/en/0420515586/s-a-therabel-pharma-n-v. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Busy address KBO

20 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

S.A Therabel-Pharma N.V. from Vorst, company number BE0420515586, closed financial year 2025 with a result of € -98,457 after tax. For that financial year S.A Therabel-Pharma N.V. recorded revenue of € 15.7 million and equity of € 4.1 million. Compared with financial year 2024, the result moved from € -4.8 million to € -98,457. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 10, 2026.

What it is worth Healthy

€ 4.1 million

▼ 2% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -98,457

▲ 98 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 402,211

▲ 36% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -10.1 million.

People and assets in 2025

Full-time equivalents

28.3

▼ 11.5 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 6.4 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 5.6 million

▲ 10% vs 2024

€ 199,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 42,059

▼ 33% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 3 million

▼ 16% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 75 days on average.

Taxes and wages

€ 724,788

▼ 30% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 17,005,644 Revenue 2022: € 17,005,644 First fiscal year in the series	€ 16,339,867 Revenue 2023: € 16,339,867 ▼ 4% vs 2022 (€ 17,005,644) Unfavourable step	€ 16,730,347 Revenue 2024: € 16,730,347 ▲ 2% vs 2023 (€ 16,339,867) Favourable step	€ 15,749,710 Revenue 2025: € 15,749,710 ▼ 6% vs 2024 (€ 16,730,347) Unfavourable step	▼ 6%
Profit after taxes	€ -2,262,923 Profit after taxes 2022: € -2,262,923 First fiscal year in the series	€ -2,602,764 Profit after taxes 2023: € -2,602,764 ▼ € 339,842 vs 2022 (€ -2,262,923) Unfavourable step	€ -4,756,763 Profit after taxes 2024: € -4,756,763 ▼ € 2.2 million vs 2023 (€ -2,602,764) Unfavourable step	€ -98,457 Profit after taxes 2025: € -98,457 ▲ € 4.7 million vs 2024 (€ -4,756,763) Favourable step	▲ € 4.7 million
Equity	€ 5,496,282 Equity 2022: € 5,496,282 First fiscal year in the series	€ 8,993,517 Equity 2023: € 8,993,517 ▲ 64% vs 2022 (€ 5,496,282) Favourable step	€ 4,236,754 Equity 2024: € 4,236,754 ▼ 53% vs 2023 (€ 8,993,517) Unfavourable step	€ 4,138,297 Equity 2025: € 4,138,297 ▼ 2% vs 2024 (€ 4,236,754) Unfavourable step	▼ 2%
Total debts	€ 7,770,953 Total debts 2022: € 7,770,953 First fiscal year in the series	€ 4,371,629 Total debts 2023: € 4,371,629 ▼ 44% vs 2022 (€ 7,770,953) Favourable step	€ 11,846,721 Total debts 2024: € 11,846,721 ▲ 171% vs 2023 (€ 4,371,629) Unfavourable step	€ 8,711,242 Total debts 2025: € 8,711,242 ▼ 26% vs 2024 (€ 11,846,721) Favourable step	▼ 26%
Cash	€ 953,706 Cash 2022: € 953,706 First fiscal year in the series	€ 710,445 Cash 2023: € 710,445 ▼ 26% vs 2022 (€ 953,706) Unfavourable step	€ 296,551 Cash 2024: € 296,551 ▼ 58% vs 2023 (€ 710,445) Unfavourable step	€ 402,211 Cash 2025: € 402,211 ▲ 36% vs 2024 (€ 296,551) Favourable step	▲ 36%
Retained profit	€ -2,598,718 Retained profit 2022: € -2,598,718 First fiscal year in the series	€ -5,201,483 Retained profit 2023: € -5,201,483 ▼ € 2.6 million vs 2022 (€ -2,598,718) Unfavourable step	€ -9,958,246 Retained profit 2024: € -9,958,246 ▼ € 4.8 million vs 2023 (€ -5,201,483) Unfavourable step	€ -10,056,703 Retained profit 2025: € -10,056,703 ▼ € 98,457 vs 2024 (€ -9,958,246) Unfavourable step	▼ € 98,457
Balance sheet total	€ 13,267,234 Balance sheet total 2022: € 13,267,234 First fiscal year in the series	€ 13,365,146 Balance sheet total 2023: € 13,365,146 ▲ 1% vs 2022 (€ 13,267,234) Unchanged	€ 16,083,475 Balance sheet total 2024: € 16,083,475 ▲ 20% vs 2023 (€ 13,365,146) Unchanged	€ 12,849,539 Balance sheet total 2025: € 12,849,539 ▼ 20% vs 2024 (€ 16,083,475) Unchanged	▼ 20%
Employees (FTE)	40.1 Employees (FTE) 2022: 40.1 First fiscal year in the series	39.2 Employees (FTE) 2023: 39.2 ▼ 0.9 vs 2022 (40.1) Unchanged	39.8 Employees (FTE) 2024: 39.8 ▲ 0.6 vs 2023 (39.2) Unchanged	28.3 Employees (FTE) 2025: 28.3 ▼ 11.5 vs 2024 (39.8) Unchanged	▼ 11.5

Key figures of S.A Therabel-Pharma N.V., fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to S.A Therabel-Pharma N.V.?

What happened at S.A Therabel-Pharma N.V. in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2027 Healthcare Expert Consulting SRL stepped down as director. NBB
2027 Bawip Consultants SRL stepped down as director. NBB
Jun 10, 2026 New annual accounts for financial year 2025: loss of € 98,457. Source: NBB ↗
2024 Healthcare Expert Consulting SRL became a director. NBB
2024 Bawip Consultants SRL became a director. NBB
Apr 16, 1980 New establishment in Vorst. KBO
Apr 16, 1980 Start of the company according to the CBE. KBO

In short

From € 2.3 million loss in 2022 to € 98,457 loss in 2025.

Paid € 57,230 in corporate taxes since 2022.

Pays suppliers within 75 days on average.

Original PDFs at the National Bank ↗

A new publication or filing at S.A Therabel-Pharma N.V.? We notify you, reason included.

Follow S.A Therabel-Pharma N.V.

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Directors

According to the 2025 annual accounts

Healthcare Expert Consulting SRL

Managing director · represented by Laurent Kirsch

Also active at: THERABEL IMMO, THERABEL INTERNATIONAL SERVICES

since 2024 · until 2027

Bawip Consultants SRL

Director · represented by Philippe Burtonboy

Also active at: THERABEL IMMO, THERABEL INTERNATIONAL SERVICES

since 2024 · until 2027

Establishments

Establishment units

Physical locations of this company

Registered office

Humaniteitslaan 292

1190 Vorst

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.

All companies at this address →

BIOCODEX Benelux

€ 20 million revenue · 2025

ATAG Heating Belgium

€ 11.5 million revenue · 2025

THERABEL IMMO same network

€ 396,306 revenue · 2025

CARLOS INTERNATIONAL

ALERT MANAGEMENT CONSULTANTS

€ 78,724 gross margin · 2025

+15 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0420.515.586

VAT number

BE 0420.515.586

Registered office

Humaniteitslaan 292, 1190 Vorst

Names & denominations

S.A Therabel-Pharma N.V.

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

16 April 1980

Peppol

Active · Active since 23 Jan 2026

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in medische en orthopedische artikelen

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗